Botulinum Toxin in Peripheral Neuropathic Pain
Launched by HOSPITAL AMBROISE PARÉ PARIS · Nov 30, 2010
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men or women aged 18 to 85 years Spontaneous pain with a minimal intensity of 4/10 on numerical scle Pain present for at least 6 months Pain related to painful mononeuropathy or sensory polyneuropathy Able to understand the protocol and comply to the requirements of the study Written informed consent Painful area limited to a maximum of 240 cm2
- Exclusion Criteria:
- • Facial pain Litigation (pending) Unstable condition responsible for neuropathic pain (ie, unstable immunological disease...) HIV or chemotherapy induced neuropathy Contraindications to BTX-A (neuromuscular disease, hypersensitivity, infection, coagulation disorder, pregnancy) Other pain more severe than neuropathic pain No compliance with the self diary Drug abuse or alcoholism Severe major depression Cognitive impairment Other research protocol within the last 30 days
About Hospital Ambroise Paré Paris
Hospital Ambroise Paré in Paris is a leading healthcare institution dedicated to advancing medical research and patient care. As a clinical trial sponsor, it focuses on innovative therapeutic approaches and cutting-edge treatments across various medical fields. The hospital is committed to fostering collaboration among multidisciplinary teams of healthcare professionals, researchers, and clinical experts to enhance the quality of clinical trials. With a strong emphasis on patient safety and ethical standards, Hospital Ambroise Paré aims to contribute significantly to the development of new medical therapies that improve patient outcomes and advance the field of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Limoges, , France
Sao Paulo, , Brazil
Boulogne Billancourt, , France
Patients applied
Trial Officials
Nadine ATTAL, MD PhD
Study Director
APHP and INSERM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials